Rhythm Pharmaceuticals, Inc. RYTM
112.28 USD +7.26 (+6.91%)
At closeNov 6, 2026, 7:53 PM EST
112.50 +0.22 +0.20%
After hours · Nov 6, 7:53 PM ET
104.31 Day range 113.29
74.50 52-week range 122.20
- YTD
- +4.90%
- 1 year
- +14.00%
News
benzinga.com Guggenheim Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $147 Guggenheim analyst Seamus Fernandez maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $143 to $147.
wsj.com AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals AstraZeneca recently made a roughly $10 billion offer to buy Rhythm Pharmaceuticals, according to people familiar with the matter, a deal that would expand its portfolio of rare disease treatments.
benzinga.com Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $166 Citizens analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Market Outperform and raises the price target from $160 to $166.
benzinga.com Rhythm Pharmaceuticals Receives Positive Guidance For IMCIVREE From National Institute For Health And Care Excellence To Add Adults With Bardet-Biedl Syndrome Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today…
globenewswire.com Rhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl Syndrome -- Expanded guidance based on additional evidence demonstrating the benefits of IMCIVREE in adults living with Bardet-Biedl syndrome -- BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Rhythm…
seekingalpha.com Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2026 Earnings Call Transcript Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2026 Earnings Call Transcript
benzinga.com Needham Maintains Buy on Rhythm Pharmaceuticals, Lowers Price Target to $114 Needham analyst Joseph Stringer maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target from $130 to $114.
marketbeat.com Rhythm Pharmaceuticals Q3 Earnings Call Highlights Rhythm Pharmaceuticals NASDAQ: RYTM reported third-quarter global net product sales of $92.1 million, up 29% sequentially, as the company cited a strong early U.S. launch for IMCIVREE in acquired…
benzinga.com Rhythm Pharmaceuticals Q3 2026 Earnings Call Transcript Rhythm Pharmaceuticals (NASDAQ:RYTM) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
zacks.com Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Beats Revenue Estimates Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to a loss of $0.82 per share a year ago.- benzinga.com Rhythm Pharmaceuticals Q3 EPS $(0.61) Beats $(0.72) Estimate, Sales $92.128M Beat $84.349M Estimate Rhythm Pharmaceuticals (NASDAQ:RYTM) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of $(0.72) by 15.28 percent. This is a 25.61 percent increase over losses…
globenewswire.com Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update -- Strong U.S. launch momentum for IMCIVREE ® (setmelanotide) for acquired hypothalamic obesity (HO) continues with more than 700 patient start forms as of September 30, 2026 -- -- Third quarter 2026…
globenewswire.com Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement -- Amendment revised royalty structure from low-to-mid-single digits to 1% on global net sales of Rhythm MC4R agonists, including setmelanotide, bivamelagon and RM-718 -- -- Rhythm to pay LG Chem…
benzinga.com Here’s How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years Rhythm Pharmaceuticals (NASDAQ:RYTM) has outperformed the market over the past 5 years by 40.37% on an annualized basis producing an average annual return of 51.51%. Currently, Rhythm Pharmaceuticals…- benzinga.com William Blair Initiates Coverage On Rhythm Pharmaceuticals with Outperform Rating William Blair analyst Alethia Young initiates coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform rating.
- benzinga.com JP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Lowers Price Target to $145 JP Morgan analyst Priyanka Grover maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and lowers the price target from $146 to $145.
- benzinga.com HC Wainwright & Co. Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $130 HC Wainwright & Co. analyst Raghuram Selvaraju maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $105 to $130.
benzinga.com RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $159 RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform and raises the price target from $155 to $159.- benzinga.com Here’s How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years Rhythm Pharmaceuticals (NASDAQ:RYTM) has outperformed the market over the past 5 years by 38.46% on an annualized basis producing an average annual return of 50.82%. Currently, Rhythm Pharmaceuticals…
benzinga.com Rhythm Pharmaceuticals Receives Health Canada Approval Of IMCIVREE For Additional Indication Of Weight Management In Adult And Pediatric Patients 4 Years Of Age And Older With Acquired Hypothalamic Obesity IMCIVREE was first approved by Health Canada in 2023 for weight management in adult and pediatric patients 6 years of age and older with obesity due to Bardet-Biedl syndrome (BBS), or genetically…
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Here’s How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years Rhythm Pharmaceuticals (NASDAQ:RYTM) has outperformed the market over the past 5 years by 40.53% on an annualized basis producing an average annual return of 51.66%. Currently, Rhythm Pharmaceuticals…
benzinga.com Here's How Much $100 Invested In Rhythm Pharmaceuticals 5 Years Ago Would Be Worth Today Rhythm Pharmaceuticals (NASDAQ:RYTM) has outperformed the market over the past 5 years by 40.99% on an annualized basis producing an average annual return of 52.06%. Currently, Rhythm Pharmaceuticals…
benzinga.com Deutsche Bank Initiates Coverage On Rhythm Pharmaceuticals with Hold Rating, Announces Price Target of $120 Deutsche Bank analyst David Hoang initiates coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Hold rating and announces Price Target of $120.- benzinga.com Rhythm Pharmaceuticals Receives Marketing Authorization For IMCIVREE From Japan's Ministry Of Health To Treat Acquired Hypothalamic Obesity Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today…
benzinga.com Why Is Rhythm Pharmaceuticals Stock Trading Higher On Wednesday? Rhythm Pharma shares rise after U.K. expands Imcivree authorization for acquired hypothalamic obesity in adults and children 4 and older.
benzinga.com JP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $146 JP Morgan analyst Priyanka Grover maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and raises the price target from $145 to $146.- benzinga.com Citigroup Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $143 Citigroup analyst Samantha Semenkow maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $142 to $143.
- benzinga.com RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $155 RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform and raises the price target from $141 to $155.
benzinga.com Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $160 Citizens analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Market Outperform and raises the price target from $155 to $160.
benzinga.com Full Transcript: Rhythm Pharmaceuticals Q2 2026 Earnings Call Rhythm Pharmaceuticals (NASDAQ:RYTM) released second-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. Benzinga APIs provide real-time access to…
benzinga.com Rhythm Pharmaceuticals Q2 EPS $(0.73) Beats $(0.82) Estimate, Sales $71.255M Beat $67.277M Estimate Rhythm Pharmaceuticals (NASDAQ:RYTM) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.82) by 10.98 percent. This is a 2.67 percent increase over losses…- benzinga.com Rhythm Pharmaceuticals Announces Preliminary Results From Ongoing Phase 2 Trial Evaluating RM-718 In Patients With Acquired Hypothalamic Obesity; BMI Reductions Consistent With Setmelanotide And Bivamelagon; Sees -11.6% Mean Reduction In BMI From Baseline At Week Eleven patients with acquired HO were enrolled in the ongoing, open-label trial. Key preliminary findings include:-11.6% reduction in mean BMI from baseline (n=7) after 16 weeks of RM-718;RM-718…
- benzinga.com JP Morgan Initiates Coverage On Rhythm Pharmaceuticals with Overweight Rating, Announces Price Target of $145 JP Morgan analyst Priyanka Grover initiates coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight rating and announces Price Target of $145.
- benzinga.com Rhythm Pharmaceuticals Announces That Results From Its Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide, A Melanocortin-4 Receptor Agonist, In Patients With Acquired Hypothalamic Obesity Have Been Published In The New England Journal Of Medicine Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced…
- benzinga.com RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $141 RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform and raises the price target from $137 to $141.
- benzinga.com Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $151 Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $143 to $151.
- benzinga.com Rhythm Pharmaceuticals Presents Data From Multiple Presentations At Endocrine Society's Annual Meeting Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced…
benzinga.com Why Is Rhythm Pharma Stock Jumping Today? Rhythm Pharma Phase 2 data showed improvements in BMI, body composition, hunger symptoms, and behavior in PWS patients.- benzinga.com Wells Fargo Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $155 Wells Fargo analyst Derek Archila maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and raises the price target from $144 to $155.
- benzinga.com Reported Saturday, Rhythm Pharmaceuticals Presents Phase 2 Data Showing Setmelanotide Achieves 3.06% Mean BMI Reduction And Clinically Meaningful Hyperphagia Improvements In Prader-Willi Syndrome Patients At ENDO 2026 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in…
- benzinga.com Rhythm Pharmaceuticals To Present Interim Phase 2 Setmelanotide Data In Prader-Willi Syndrome On June 13 At 9:00 a.m. ET Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced…
- benzinga.com Rhythm Pharmaceuticals Announces Publication Of An Evidence-Based, Consensus-Driven Diagnostic Algorithm For Bardet-Biedl Syndrome "Streamlining Diagnosis of Bardet-Biedl Syndrome: New Diagnostic Algorithm with Updated Criteria," was published in the peer-reviewed American Journal of Medical Genetics.This simplified and…
- benzinga.com Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $143 Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $140 to $143.
benzinga.com Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results Rhythm Pharmaceuticals (NASDAQ: RYTM) reported better-than-expected earnings, with strong demand for IMCIVREE and potential launches in Europe and Japan.- benzinga.com RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $137 RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform and raises the price target from $136 to $137.
- benzinga.com Wells Fargo Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $144 Wells Fargo analyst Derek Archila maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and raises the price target from $143 to $144.
benzinga.com Full Transcript: Rhythm Pharmaceuticals Q1 2026 Earnings Call 
benzinga.com Earnings Scheduled For May 5, 2026 - benzinga.com Rhythm Pharmaceuticals Presents New Data At The Pediatric Endocrine Society Annual Meeting Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced…